WO1998056363A1 - Knobby nanospheres - Google Patents
Knobby nanospheres Download PDFInfo
- Publication number
- WO1998056363A1 WO1998056363A1 PCT/US1998/012126 US9812126W WO9856363A1 WO 1998056363 A1 WO1998056363 A1 WO 1998056363A1 US 9812126 W US9812126 W US 9812126W WO 9856363 A1 WO9856363 A1 WO 9856363A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoparticle
- polypeptide
- linking molecule
- gene delivery
- delivery vehicle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- This invention is related to improved vehicles for delivering substances to the intracellular milieu.
- the nanoparticle comprises a polymeric cation and a polyanion, wherein the polyanion consists of nucleic acids, wherein a polypeptide is attached to the surface of said nanoparticle, wherein the polypeptide comprises the knob domain of adenovirus fiber protein.
- a method of forming solid nanoparticles for delivery to target cells comprises the steps of: forming solid nanoparticles by coacervation of a polyanion consisting of nucleic acids and a polymeric cation; adhering a molecular species to the surface of the nanoparticles wherein the molecular species is selected from the group consisting of a polypeptide comprising the knob domain of adenovirus fiber protein and a linking molecule, wherein if the molecular species is a linking molecule the method further comprises the step of binding a polypeptide comprising the knob domain of adenovirus fiber protein to the linking molecule.
- a method for introducing genes into cells comprises the steps of: incubating (a) cells to be transfected with (b) solid nanoparticles comprising a coacervate of a polymeric cation and a polyanion consisting of nucleic acids, wherein a polypeptide is attached to said nanoparticles' surface, said polypeptide comprising the knob domain of adenovirus fiber protein.
- a gene delivery vehicle is provided. A polypeptide is attached to the surface of the gene delivery vehicle. The polypeptide comprises the knob domain of adenovirus fiber protein.
- FIG. 1 Improvement of transfection efficiency of DNA-chitosan nanospheres into 293 cells with Knob conjugated on the surface of the nanospheres. The DNA encoded luciferase. Luciferase activity is shown.
- Figure 2. Improvement of transfection efficiency of DNA-chitosan nanospheres into HeLa cells with Knob conjugated on the surface of the nanospheres. The DNA encoded luciferase. Luciferase activity is shown. DETAILED DESCRIPTION
- Knob domain of the fiber protein of adenovirus can be conjugated to nanospheres or other gene delivery vehicles and that they enhance the uptake of the gene delivery vehicles by cells.
- the Knob domain functions as a specific ligand to a cell surface component, and that the binding of the ligand to the cell surface component effects internalization of the gene delivery vehicles.
- Nanospheres are solid particles made by the complex coacervation of a polycation and a polyanion.
- the polycation can be gelatin, actin, tubulin, cytochromoe C, serum albumin, or histones, or other similar positively charged protein.
- the polycation can also be a polysaccharide such as chitosan, proteoglycan, methylcellulose, amylose, or starch.
- the polyanion can be nucleic acids or chondroiton sulfate, for example.
- Other components such as low molecular weight drugs, proteins, antisense oligonucleotides, and nucleic acids such as plasmid DNAs can also be encapsulated in the nanosphere.
- Other gene delivery vehicles which may be used include protein-DNA complexes, gold particles, liposomes, and polymeric nanoparticles.
- Fiber protein is one of the capsid components of human adenovirus. Fiber protein or a portion of fiber protein, in particular the knob domain, can be covalently attached to a nanosphere.
- fiber protein facilitates the internalization of nanospheres by cells, perhaps by a specific interaction with a receptor protein. This internalization permits more drug or therapeutic agent to reach the intracellular target, thus permitting lower doses to be used than without the fiber protein. This provides both a cost savings and a safety benefit.
- the surface of nanoparticles or gene delivery vehicles can be easily derivatized for the direct coupling of targeting moieties.
- carbo- diimides can be used as a derivatizing agent.
- spacers linking molecules and derivatizing moieties on targeting ligands
- avidin-biotin can be used to indirectly couple targeting ligands to the nanoparticles.
- Biotinylated antibodies and/or other biotinylated ligands can be coupled to the avidin-coated nanoparticle surface efficiently because of the high affinity of biotin (I ⁇ lO 15 M "1 ) for avidin (Hazuda, et al. , 1990, Processing of precursor interleukin 1 beta and inflammatory disease, J. Biol. Chem. , 265:6318-22; Wilchek, et al., 1990, Introduction to avidin-biotin technology, Methods In Enzymology, 184:5-13).
- Orientation-selective attachment of IgGs can be achieved by biotinylating the antibody at the oligosaccharide groups found on the F c portion (O'Shannessy, et al., 1984, A novel procedure for labeling immunoglobulins by conjugation to oligosaccharides moieties, Immunol. Lett. , 8:273-277).
- This design helps to preserve the total number of available binding sites and renders the attached antibodies less immunogenic to F c receptor-bearing cells such as macrophages.
- Spacers other than the avidin-biotin bridge can also be used, as are known in the art.
- Staphylococcal protein A can be coated on the nanoparticles for binding the F c portions of immunoglobulin molecules to the nanoparticles.
- Cross-linking of linking molecules or targeting ligands to the nanoparticle is used to promote the stability of the nanoparticle as well as to covalently affix the linking molecule or targeting ligand to the nanoparticle.
- the degree of cross- linking directly affects the rate of nucleic acids release from the microspheres.
- Cross-linking can be accomplished using glutaraldehyde, carbodiimides such as EDC (l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, DCC (N,N'- dicyclohexylcarbodiimide), carboxyls (peptide bond) linkage, DSS (Disuccinimidyl suberate), SPDP (N-succinimidyl 3-[2-pyridyldithio]propionate bis (sulfosuccinimidyl) suberate), dimethylsuberimidate, etc.
- EDC l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
- DCC N,N'- dicyclohexylcarbodiimide
- carboxyls (peptide bond) linkage DSS (Disuccinimidyl suberate)
- SPDP N-succinimidyl 3-[2-
- the nanoparticles of the present invention have good loading properties. Typically, following the method of the present invention, nanoparticles having at least 5% (w/w) nucleic acids can be achieved. Preferably the loading is greater than 10 or 15% nucleic acids. Often nanoparticles of greater than 20 or 30%, but less than 40 or 50% nucleic acids can be achieved. Typically encapsulation efficiencies of nucleic acids into nanoparticles of greater than 95% can be achieved.
- the method of the present invention involves the coacervation of polymeric cations and nucleic acids. Because this process depends on the interaction of the positively charged polymeric cations and the negatively charged nucleic acids it can be considered as a complex coacervation process. However, sodium sulfate (or ethanol) induces the coacervation reaction by inducing a phase transition, and therefore it could also be considered as a simple coacervation reaction. Nucleic acids are present in the coacervation mixture at a concentration of between 1 ng/ml to 500 g/ml. Desirably the nucleic acids are at least about 2-3 kb in length. Sodium sulfate is present at between 7 and 43 mM.
- Gelatin or other polymeric cation is present at between about 2 and 7% in the coacervation mixture. Unlike viral vectors, which cannot deliver genes larger than 10 kb, the nanoparticle delivery system of the present invention does not have such size limitations. Nucleic acid molecules of greater than about 2 kb can be used, and nucleic acid molecules even greater than 10 kb may be used. Typically nucleic acids in the range of 2 to 10 kb, 5 to 15 kb, and even 10-50 kb can be encapsulated.
- the range of possible targets is dependent on the route of injection, e.g., intravenous or intraarterial, subcutaneous, intra-peritoneal, intrathecal, etc.
- the specificity of this delivery system is affected by the accessibility of the target to blood borne nanoparticles, which in turn, is affected by the size range of the particles. Size of the particles is affected by temperature, component concentration, and pH in the coacervation mixture. The particles can also be size-fractionated, e.g., by sucrose gradient ultracentrifugation. Suitable sizes of nanoparticles are less than 3 ⁇ m, preferably less than 2 ⁇ m, 1 ⁇ m, and even as low as 0.1 ⁇ m.
- Particles with size less than 150 nanometers can access the interstitial space by traversing through the fenestrations that line most blood vessels walls. Under such circumstances, the range of cells that can be targeted is extensive.
- An abbreviated list of cells that can be targeted includes the parenchymal cells of the liver sinusoids, the f ⁇ broblasts of the connective tissues, the cells in the Islets of Langerhans in the pancreas, the cardiac myocytes, the Chief and parietal cells of the intestine, osteocytes and chondrocytes in the bone, keratinocytes, nerve cells of the peripheral nervous system, epithelial cells of the kidney and lung, Sertoli cells of the testis, etc.
- the targetable cell types include erythrocytes, leukocytes (i.e. monocytes, macrophages, B and T lymphocytes, neutrophils, natural killer cells, progenitor cells, mast cells, eosinophils), platelets, and endothelial cells.
- leukocytes i.e. monocytes, macrophages, B and T lymphocytes
- neutrophils natural killer cells
- progenitor cells i.e. monocytes, macrophages, B and T lymphocytes
- mast cells eosinophils
- platelets e.g., eothelial cells
- endothelial cells e.g., endothelial cells.
- the targetable cells include all cells that resides in the connective tissue (e.g., fibroblasts, mast cells, etc.), Langerhans cells, keratinocytes, and muscle cells.
- the targetable cells include neurons, glial cells, astrocytes,
- EXAMPLE 1 Expression and Purification of the Knob Domain of the Adenovirus Type 5 Fiber Protein
- the knob domain was cloned by PCR amplification using cloned Ad5 plasmid DNA (pJM17, McGrory, et al. , 1988) as the template and specific oligonucleotides designed to facilitate the insertion of the PCR product into the bacterial expression vector pET15b (Novagen).
- the sequences of the two primers used were CTCGAGGGTGCCATTACAGTAGGAAACAAAAATAATGATAAG (5 1 oligonucleotide) and
- GGATCCTTATTCTTGGGC AATGTATG AAA AAGTGTAAGAGG 3 ' oligonucleotide, which are partially complementary to specific Ad5 fiber sequences (Chroboczek and Jacrot, 1987).
- the PCR product of approximately 600 bp was purified by the PCR purification kit (Qiagen), and digested by BamHI and Xhol, then directionally ligated into BamHI-XhoI-digested pET15b.
- BL21(DE3) cells used as the host strain.
- a clone containing the appropriate recombinant plasmid was identified by restriction enzyme digestion.
- the expression of the knob was induced by 0.1 mM IPTG in LB medium and characterized by Western Blot.
- N-terminus Cells from 100 ml of culture were spun down and resuspended in 18 ml of Native Binding Buffer (20 mM phosphate, 500 mM NaCl, pH 7.8). One ml of 1 % Triton X-100TM was added to achieve good solubilization. The cells were disrupted by sonication in short bursts (20 sec/burst, total 80 seconds), and the cell debris and DNA were precipitated at 10,000 x g for 10 minutes. The pre-equilibrated resin in the column was resuspended with four 5 ml lysate aliquots and gently rocked for 10 minutes to allow for binding of the polyhistidine-containing protein. The resin was then settled by centrifugation, and the supernatant was aspirated. The column was washed three times with 4 ml of Native Binding Buffer, twice with 4 ml Native Wash Buffer (20 mM phosphate,
- Knob-SH concentration of Knob derivative
- the mixture was stirred at room temperature for 30 min before 50 mL of 1 M glycine was added to quench the reaction, followed by addition of 250 mg of Knob-SH. After reaction for 60 minutes, the mixture was subjected to ultracentrifugation to harvest the nanospheres.
- Nanospheres containing 1 mg of DNA were incubated with 1.0-5.0 x 105 cells in each well (pre-plated in 12 well plate) at 37° C and 5% CO 2 in DMEM containing 1% fetal bovine serum (FBS), 2 mM L-glutamine, 50 units/mL penicillin, 50 mg/mL streptomycin, and 10 mg/ mL gentamycin for 4 hours, followed by changing the medium to fresh complete medium (DMEM containing 10% FBS). Cells were cultured for 3 days before assay. Transfection using Lipofectamine (BRL, Gaithersburg, MD, liposome method) was used as control. Luciferase gene expression levels were measured by assaying Luciferase activity in permeabilized cell extracts (Promega, Madison, WI). The light units (LU) were normalized to protein concentration in the cell extracts measured by the BCA method.
- FBS fetal bovine serum
- LU light units
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU78365/98A AU7836598A (en) | 1997-06-13 | 1998-06-11 | Knobby nanospheres |
EP98926552A EP0988030A1 (en) | 1997-06-13 | 1998-06-11 | Knobby nanospheres |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4949697P | 1997-06-13 | 1997-06-13 | |
US60/049,496 | 1997-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998056363A1 true WO1998056363A1 (en) | 1998-12-17 |
Family
ID=21960134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/012126 WO1998056363A1 (en) | 1997-06-13 | 1998-06-11 | Knobby nanospheres |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0988030A1 (en) |
AU (1) | AU7836598A (en) |
WO (1) | WO1998056363A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029307A1 (en) * | 1997-12-12 | 1999-06-17 | Massachusetts Institute Of Technology | SUB-100nm BIODEGRADABLE POLYMER SPHERES CAPABLE OF TRANSPORTING AND RELEASING NUCLEIC ACIDS |
WO2000033886A1 (en) * | 1998-12-04 | 2000-06-15 | Genzyme Corporation | Dry powder complexes for gene delivery |
EP1450751A2 (en) * | 2001-07-10 | 2004-09-01 | North Carolina State University | Nanoparticle delivery vehicle |
EP2360275A1 (en) * | 2000-11-15 | 2011-08-24 | Minerva Biotechnologies Corporation | Oligonucleotide identifiers |
WO2012136734A1 (en) * | 2011-04-05 | 2012-10-11 | Tracesa Ltd. | Fluid identification system and production and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028817A1 (en) * | 1996-02-09 | 1997-08-14 | Cheng Pi Wan | Receptor ligand-facilitated delivery of biologically active molecules |
WO1998001162A2 (en) * | 1996-07-09 | 1998-01-15 | The Johns Hopkins University | Gene delivery system |
-
1998
- 1998-06-11 EP EP98926552A patent/EP0988030A1/en not_active Ceased
- 1998-06-11 AU AU78365/98A patent/AU7836598A/en not_active Abandoned
- 1998-06-11 WO PCT/US1998/012126 patent/WO1998056363A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028817A1 (en) * | 1996-02-09 | 1997-08-14 | Cheng Pi Wan | Receptor ligand-facilitated delivery of biologically active molecules |
WO1998001162A2 (en) * | 1996-07-09 | 1998-01-15 | The Johns Hopkins University | Gene delivery system |
Non-Patent Citations (7)
Title |
---|
C.K. GOLDMAN ET AL.: "TARGETED GENE DELIVERY TO KAPOSI'S SARCOMA CELLS via THE FIBROBLAST GROWTH FACTOR RECEPTOR.", CANCER RESEARCH, vol. 57, no. 8, 15 April 1997 (1997-04-15), MD US, pages 1447 - 1451, XP002079943 * |
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; DOUGLAS J T ET AL: "Targeted gene delivery by tropism-modified adenoviral vectors.", XP002079945 * |
DOUGLAS J T ET AL: "Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors.", NEUROMUSCULAR DISORDERS, (1997 JUL) 7 (5) 284-98. REF: 98 JOURNAL CODE: BJS. ISSN: 0960-8966., ENGLAND: United Kingdom, XP002079944 * |
MAO H.-Q. ET AL: "DNA-chitosan nanospheres: Derivatization and storage stability.", PROCEEDINGS OF THE CONTROLLED RELEASE SOCIETY, (1997) -/24 (671-672). REFS: 4 ISSN: 1022-0178 CODEN: 58GMAH, United States, XP002079941 * |
NATURE BIOTECHNOLOGY, (1996 NOV) 14 (11) 1574-8. JOURNAL CODE: CQ3. ISSN: 1087-0156., United States * |
ROGERS B E ET AL: "USE OF A NOVEL CROSS-LINKING METHOD TO MODIFY ADENOVIRUS TROPISM", GENE THERAPY, vol. 4, no. 12, December 1997 (1997-12-01), pages 1387 - 1392, XP002069405 * |
ROY, KRISHNENDU ET AL: "DNA - chitosan nanospheres: transfection efficiency and cellular uptake", PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1997), 24TH, 673-674 CODEN: PCRMEY;ISSN: 1022-0178, 1997, XP002079942 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029307A1 (en) * | 1997-12-12 | 1999-06-17 | Massachusetts Institute Of Technology | SUB-100nm BIODEGRADABLE POLYMER SPHERES CAPABLE OF TRANSPORTING AND RELEASING NUCLEIC ACIDS |
US6254890B1 (en) | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
WO2000033886A1 (en) * | 1998-12-04 | 2000-06-15 | Genzyme Corporation | Dry powder complexes for gene delivery |
EP2360275A1 (en) * | 2000-11-15 | 2011-08-24 | Minerva Biotechnologies Corporation | Oligonucleotide identifiers |
EP1990040A1 (en) * | 2001-07-10 | 2008-11-12 | North Carolina State University | Nanoparticle delivery vehicle |
US7332586B2 (en) | 2001-07-10 | 2008-02-19 | North Carolina State University | Nanoparticle delivery vehicle |
EP1450751A4 (en) * | 2001-07-10 | 2006-03-22 | Univ North Carolina State | Nanoparticle delivery vehicle |
EP1450751A2 (en) * | 2001-07-10 | 2004-09-01 | North Carolina State University | Nanoparticle delivery vehicle |
WO2012136734A1 (en) * | 2011-04-05 | 2012-10-11 | Tracesa Ltd. | Fluid identification system and production and use thereof |
EP2942405A1 (en) * | 2011-04-05 | 2015-11-11 | Tracesa Ltd | Fluid identification system and production and use thereof |
US9322056B2 (en) | 2011-04-05 | 2016-04-26 | Tracesa, Ltd. | Fluid identification system and production and use thereof |
AU2012238638B2 (en) * | 2011-04-05 | 2017-06-08 | Tracesa Ltd. | Fluid identification system and production and use thereof |
US9926591B2 (en) | 2011-04-05 | 2018-03-27 | Tracesa, Ltd. | Fluid identification system and production and use thereof |
EP3382038A1 (en) * | 2011-04-05 | 2018-10-03 | Tracesa Ltd | Fluid identification system and production and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0988030A1 (en) | 2000-03-29 |
AU7836598A (en) | 1998-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5972707A (en) | Gene delivery system | |
US6025337A (en) | Solid microparticles for gene delivery | |
AU749032B2 (en) | Therapeutic nanospheres | |
US5994316A (en) | Method of preparing polynucleotide-carrier complexes for delivery to cells | |
Guy et al. | Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy | |
Garnett | Gene-delivery systems using cationic polymers | |
US5728399A (en) | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells | |
TWI267380B (en) | Nucleic acid-containing complex | |
JP2004516809A (en) | Molecular transport vehicles for transporting selected compounds to targets | |
Khondee et al. | Calcium condensed LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells | |
JP2002537318A (en) | Antibody-targeted fragment immunoliposomes for systemic gene delivery | |
KR20080100376A (en) | Agent-enriched nanoparticles based on hydrophilic proteins | |
JP2003530360A (en) | Peptide conjugates for drug delivery | |
EP1098632A1 (en) | Charge reversal of polyion complexes | |
WO2000061190A2 (en) | Treatment of intracellular infection | |
EP0988030A1 (en) | Knobby nanospheres | |
Mok et al. | Functional polymers for targeted delivery of nucleic acid drugs | |
US8202544B2 (en) | High capacity non-viral vectors | |
JP2000506388A (en) | Use of viral cis-acting post-transcriptional regulatory sequences to increase expression of intronless genes with near common splice sites | |
CA2198361A1 (en) | Intracellular delivery of chemical agents to a specific cell type | |
CN114081965B (en) | Exosome delivery carrier and preparation method and application thereof | |
WO1999015687A1 (en) | Multicomponent polynucleotide complex for high efficiency cell transfection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998926552 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999503204 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998926552 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998926552 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998926552 Country of ref document: EP |